Economy Blog » Dendreon’s Move Still Leaves Many Questions (DNDN)

Economy Blog
Everything about the economy in a single blog

RSS | Visita nuestra web

Dendreon’s Move Still Leaves Many Questions (DNDN)

Dendreon Corp. (NASDAQ: DNDN) was an incredible performer today, and one which makes you wonder how well it would have done had the stock market not been so ugly. Its interim data from Phase III PROVENGE IMPACT trial showed that the IDMC observed no safety concerns, and it recommended that the study continue. The company itself has completed the planned interim analysis of the Phase III, randomized, double-blind, placebo-controlled IMPACT clinical trial designed to assess the safety and efficacy of PROVENGE in men with metastatic androgen-independent prostate cancer. We do want to outline how that despite this data being good and despite it being an active day trader stock again, Dendreon is not suddenly a slam dunk and still has many risks associated with it. …
Original Source: www.247wallst.com